Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

被引：0
|
作者：
Bridges, J. [1 ]
De La Cruz, M. [2 ]
Pavilack, M. [3 ]
Flood, E. [2 ]
Janssen, E. [2 ]
Chehab, N. [3 ]
Fernandes, A. [3 ]
机构：
[1] Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA
[2] Icon, Gaithersburg, MD USA
[3] Astrazeneca, Med Affairs Oncol, Gaithersburg, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
treatment preference; EGFR-TKI; NSCLC;
D O I：
10.1016/j.jtho.2018.08.288
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10.01
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [21] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
    Tanaka, Midori
    Ishii, Hidenobu
    Moribuchi, Hayato
    Naito, Yoshiko
    Matsuo, Norikazu
    Nakamura, Masayuki
    Tokito, Takaaki
    Azuma, Koichi
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 715 - 717
  • [22] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
    Midori Tanaka
    Hidenobu Ishii
    Hayato Moribuchi
    Yoshiko Naito
    Norikazu Matsuo
    Masayuki Nakamura
    Takaaki Tokito
    Koichi Azuma
    Kazuhiko Yamada
    Tomoaki Hoshino
    Investigational New Drugs, 2018, 36 : 715 - 717
  • [23] Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
    Kobayashi, Keigo
    Tan, Aaron C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [24] Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
    Lee, June Koo
    Kim, Tae Min
    Koh, Youngil
    Lee, Se-Hoon
    Kim, Dong-Wan
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Yang, Seok-Chul
    Kim, Young Tae
    Kim, Young-Whan
    Heo, Dae Seog
    Bang, Yung-Jue
    LUNG CANCER, 2012, 77 (02) : 460 - 463
  • [25] KRAS mutation in the primary or acquired resistance of Chinese NSCLC to EGFR tyrosine kinase inhibitors
    Chen, H.
    Wu, Y.
    Zhang, X.
    Chen, Z.
    Guo, A.
    Cheng, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
    Pan, Minggui
    Santamaria, Monica
    Wollman, David B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (10): : 603 - 607
  • [27] CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
    Minggui Pan
    Monica Santamaria
    David B Wollman
    Nature Clinical Practice Oncology, 2007, 4 : 603 - 607
  • [28] CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression
    Jurica, James M.
    Carsten, Billie
    Balakhani, Sudabeh
    Haag, Mary M.
    Aisner, Dara L.
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2024, 25 (01) : 77 - 79
  • [29] EGFR - TYROSINE KINASE INHIBITOR AS FIRST LINE TREATMENT IN METASTATIC LUNG ADENOCARCINOMA
    Febriani, Anna
    Wulandari, Laksmi
    Hariadi, Slamet
    Wibisono, Yusuf
    RESPIROLOGY, 2010, 15 : 67 - 67
  • [30] EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
    Dong, Rui-Fang
    Zhu, Miao-Lin
    Liu, Ming-Ming
    Xu, Yi-Ting
    Yuan, Liu-Liu
    Bian, Jing
    Xia, Yuan-Zheng
    Kong, Ling-Yi
    PHARMACOLOGICAL RESEARCH, 2021, 167
12345